Hovione Granted Patent for XCaps
Hovione has been granted a U.S. patent for a capsule-based, low-cost dry powder inhaler (DPI), the company reports. Proposed for most pulmonary disease treatments, including those for asthma, COPD, and infection, XCaps features two operating components, which the company says promotes cost savings and ease of use.
“The XCaps addresses a gap for a simple, easy to use, cost effective, multiple use, capsule based inhalation device,” said Gonçalo Andrade, Business Development Manager, in a press release. “This allows our business partners to take advantage of additional patent protection for their inhalation drug product and effective drug product life cycle management.”
Adds Peter Villax, Vice-President and co-inventor of the device: “We give our customers an edge in speed of development because we are perhaps the only independent company developing DPIs with expertise in every aspect of the inhaled drug development process. This patent grant in the US within 30 months of initial filing underpins Hovione’s capabilities in innovation and intellectual property management, to successfully design, develop and deliver innovative products.” Hovione had previously developed TwinCaps for the delivery of the anti-viral drug, laninamivir, to treat influenza and is now approved in Japan and marketed by licensee Daiichi-Sankyo as part of its Inavir product, Hovione reported.
Hovione inhalers are offered for licensing, together with formulation and particle engineering services on a fee for service basis, the company reports. It has also developed a line of inhalation-grade APIs, including fluticasone, salmeterol, mometasone, and tiotropium. For more information about XCaps please visit www.hovione.com/inhale